LULICAN

This brand name is authorized in Nigeria.

Active ingredients

The drug LULICAN contains a combination of these active pharmaceutical ingredients (APIs):

1	Clotrimazole UNII G07GZ97H65 - CLOTRIMAZOLE
	Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the fungal cytoplasmic membrane. Clotrimazole has a broad antimycotic spectrum of action in vitro and in vivo, which includes dermatophytes, yeasts, moulds, etc.
	Read more about Clotrimazole
2	Ichthammol UNII NQ14646378 - ICHTHAMMOL

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A11-100635	Cream	Lulican cream CREAM 0.2%; 0.5% 1 x 20 g (in Alu tube)	Cream White to off white cream and very smooth when applied to the skin 37 NF-PP-383174 LULICAN cream Clotrimazole and Ichthammol cream Each g of tube contains   Clotrimazole BP (0.5% w/w) 5.25 mg Ichthammol BP (0.2% w/w) 2 mg Cetomacrogol 1000 BP 15 mg Cetostearyl Alcohol BP 60 mg Glycerol Monostearate BP 20 mg Liquid Paraffin (Light) BP 80 mg Hard Paraffin BP 63.8 mg Benzyl Alcohol BP 15 mg Sodium Methyl Paraben BP 1.5 mg Sodium Propyl Paraben BP 0.9 mg Sodium Phosphate BP 1 mg Sodium Acid Phosphate BP 0.2 mg Propylene Glycol BP 27 mg Fragrance (Lavender) IH 6 mg Freshly Boiled Purified Water BP 702.35 mg A11-100635 Drugs Nigerian Products 20g OTC 11/6/2023 SAGAR VITACEUTICALS NIGERIA LTD., PLOT 2, LADIPO OLUWOLE STREET 9022977711 suptpharm@svnl.in Sagar Vitaceuticals Nigeria Limited, Plot 2, Ladipo Oluwole Street, Off Oba Akran Avenue, Ikeja, Lagos, Nigeria, Nigeria	21/12/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D01AC01	Clotrimazole	D Dermatologicals → D01 Antifungals for dermatological use → D01A Antifungals for topical use → D01AC Imidazole and triazole derivatives
Discover more medicines within D01AC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A11-100635